185 related articles for article (PubMed ID: 33755735)
1. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.
Pirasteh A; Sorra EA; Marquez H; Sibley RC; Fielding JR; Vij A; Rich NE; Arroyo A; Yopp AC; Khatri G; Singal AG; Yokoo T
Abdom Radiol (NY); 2021 Aug; 46(8):3708-3716. PubMed ID: 33755735
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization.
Kierans AS; Najjar M; Dutruel SP; Gavlin A; Chen C; Lee MJ; Askin G; Halazun KJ
Clin Imaging; 2021 Dec; 80():117-122. PubMed ID: 34303189
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
[TBL] [Abstract][Full Text] [Related]
4. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization.
Ormiston WEL; Yarmohammadi H; Lobaugh S; Schilsky J; Katz SS; LaGratta M; Velayati S; Zheng J; Capanu M; Do RKG
Abdom Radiol (NY); 2021 Aug; 46(8):3738-3747. PubMed ID: 32968863
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
[TBL] [Abstract][Full Text] [Related]
6. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization.
Bartnik K; Podgórska J; Rosiak G; Korzeniowski K; Rowiński O
Abdom Radiol (NY); 2022 Jan; 47(1):115-122. PubMed ID: 34581927
[TBL] [Abstract][Full Text] [Related]
7. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38605217
[TBL] [Abstract][Full Text] [Related]
8. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
9. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
[TBL] [Abstract][Full Text] [Related]
10. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
12. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
13. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
[TBL] [Abstract][Full Text] [Related]
14. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
Sato Y; Watanabe H; Sone M; Onaya H; Sakamoto N; Osuga K; Takahashi M; Arai Y;
Ups J Med Sci; 2013 Mar; 118(1):16-22. PubMed ID: 23167460
[TBL] [Abstract][Full Text] [Related]
15. Added Value of CT Arterial Subtraction Images in Liver Imaging Reporting and Data System Treatment Response Categorization for Transcatheter Arterial Chemoembolization-Treated Hepatocellular Carcinoma.
Huh J; Kim B; Lee JH; Won JH; Kim J; Kwon Y; Kim JK
Invest Radiol; 2021 Feb; 56(2):109-116. PubMed ID: 33405431
[TBL] [Abstract][Full Text] [Related]
16. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes.
King MJ; Tong A; Dane B; Huang C; Zhan C; Shanbhogue K
Eur J Radiol; 2020 Dec; 133():109351. PubMed ID: 33096408
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
18. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
19. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
[TBL] [Abstract][Full Text] [Related]
20. Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis.
Kang JH; Choi SH; Lee JS; Kim KW; Kim SY; Lee SS; Byun JH
Eur Radiol; 2021 Sep; 31(9):6856-6867. PubMed ID: 33713172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
